Oxyle AG is a Swiss company based in Zurich that specializes in wastewater treatment aimed at removing persistent and toxic micropollutants from water sources. Established in 2020, the company has developed a novel technology that effectively degrades hazardous substances, including pharmaceuticals, personal-care products, endocrine-disrupting chemicals, pesticides, and industrial chemicals. Oxyle serves a diverse clientele, including the pharmaceutical, biotech, chemical, food and beverage sectors, research laboratories, hospitals, and wastewater treatment facilities. Its innovative approach not only helps clients comply with regulatory standards but also offers a sustainable alternative to wastewater incineration, thereby contributing to reduced CO2 emissions.
Oxyle
Pre Seed Round in 2022
Oxyle AG is a Swiss company based in Zurich that specializes in wastewater treatment aimed at removing persistent and toxic micropollutants from water sources. Established in 2020, the company has developed a novel technology that effectively degrades hazardous substances, including pharmaceuticals, personal-care products, endocrine-disrupting chemicals, pesticides, and industrial chemicals. Oxyle serves a diverse clientele, including the pharmaceutical, biotech, chemical, food and beverage sectors, research laboratories, hospitals, and wastewater treatment facilities. Its innovative approach not only helps clients comply with regulatory standards but also offers a sustainable alternative to wastewater incineration, thereby contributing to reduced CO2 emissions.
Mobio Interactive
Seed Round in 2020
Mobio Interactive Inc. specializes in creating digital tools that enhance mental health and well-being for both consumers and clinical populations. Founded in 2014 and headquartered in Toronto, Canada, with additional offices in Zurich, Switzerland, and Shanghai, China, the company has developed applications such as Am Mindfulness, Wildflowers Mindfulness, and Actify Mindfulness. These applications provide medical-grade mindfulness training while objectively measuring the effectiveness of mindfulness practices through advanced analytics. Mobio's AI-powered digital theragnostic platform delivers clinically validated psychotherapy programs tailored to individual patients, utilizing digital biomarkers to assess human brain states without the need for wearable devices. The platform ensures secure and private interactions for users, allowing them to engage with mental health resources from anywhere in the world.
Achiko AG is a technology-driven company based in Zürich, Switzerland, with additional offices in Jakarta and Singapore. Established in 2018, it focuses on developing innovative diagnostic solutions and mobile health applications. Its flagship product is a rapid, affordable, and accurate Covid-19 test, which is accompanied by a user-friendly app that serves as a digital health passport. The company's biotechnology division, AptameX, specializes in creating aptamer-based diagnostics, while its digital health technology division, Teman Sehat, enhances the user experience through companion health apps. Achiko's products are designed to be cost-effective and can be rapidly synthesized, positioning the company to address a wide array of disease diagnostics and therapeutic indications in the evolving healthcare landscape.
Mobio Interactive
Pre Seed Round in 2017
Mobio Interactive Inc. specializes in creating digital tools that enhance mental health and well-being for both consumers and clinical populations. Founded in 2014 and headquartered in Toronto, Canada, with additional offices in Zurich, Switzerland, and Shanghai, China, the company has developed applications such as Am Mindfulness, Wildflowers Mindfulness, and Actify Mindfulness. These applications provide medical-grade mindfulness training while objectively measuring the effectiveness of mindfulness practices through advanced analytics. Mobio's AI-powered digital theragnostic platform delivers clinically validated psychotherapy programs tailored to individual patients, utilizing digital biomarkers to assess human brain states without the need for wearable devices. The platform ensures secure and private interactions for users, allowing them to engage with mental health resources from anywhere in the world.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.